Kathmere Capital Management LLC Takes Position in Stryker Co. (NYSE:SYK)

Kathmere Capital Management LLC purchased a new position in Stryker Co. (NYSE:SYK - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 809 shares of the medical technology company's stock, valued at approximately $291,000.

Several other large investors also recently bought and sold shares of the company. Dunhill Financial LLC boosted its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 37 shares during the period. Centennial Bank AR lifted its holdings in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock worth $32,000 after buying an additional 48 shares in the last quarter. Darwin Wealth Management LLC purchased a new position in Stryker in the 3rd quarter valued at about $36,000. Hara Capital LLC acquired a new stake in shares of Stryker during the third quarter valued at about $42,000. Finally, HBW Advisory Services LLC purchased a new stake in shares of Stryker during the third quarter worth about $42,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Transactions at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.50% of the company's stock.

Stryker Stock Performance

Shares of Stryker stock traded up $2.12 during trading on Friday, hitting $383.91. 1,727,106 shares of the stock were exchanged, compared to its average volume of 1,369,246. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker Co. has a 12 month low of $307.23 and a 12 month high of $398.20. The stock's fifty day moving average is $375.35 and its 200 day moving average is $358.48. The stock has a market cap of $146.35 billion, a PE ratio of 41.15, a P/E/G ratio of 2.51 and a beta of 0.95.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analysts' expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.46 EPS. As a group, sell-side analysts anticipate that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date of this dividend is Tuesday, December 31st. This is a positive change from Stryker's previous quarterly dividend of $0.80. Stryker's payout ratio is 36.01%.

Analyst Ratings Changes

SYK has been the subject of a number of recent analyst reports. BTIG Research raised their price objective on Stryker from $383.00 to $394.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Royal Bank of Canada reissued an "outperform" rating and set a $425.00 price target on shares of Stryker in a research report on Tuesday, January 7th. JPMorgan Chase & Co. lifted their price target on shares of Stryker from $375.00 to $420.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 30th. UBS Group increased their price objective on shares of Stryker from $366.00 to $370.00 and gave the company a "neutral" rating in a research note on Wednesday, October 30th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $442.00 target price on shares of Stryker in a research report on Tuesday, January 7th. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat.com, Stryker has an average rating of "Moderate Buy" and an average price target of $405.80.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.